Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Harvard Business School

Last Updated: December 2, 2022

Details for Patent: 7,153,964

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 7,153,964
Title:Pyrimidine compounds
Abstract: Pyrimidine derivatives of formula (I) wherein: Qh.sub.1 and Q.sub.2 are independently selected from aryl or carbon linked heteroaryl optionally substituted as defined within; and one of Q.sub.1 and Q.sub.2 or both Q.sub.1 and Q.sub.2 is substituted on a ring carbon by one group selected from sulphamoyl, N--(C.sub.1-4alkyl)sulphamoyl (optionally substituted by halo or hydroxy), N,N-di-(C.sub.1-4alkyl)sulphamoyl (optionally substituted by halo or hydroxy), C.sub.1-4alkylsulphonyl (optionally substituted by halo or hydroxy) or a substituent of the formula (Ia) or (Ia'): wherein Q.sub.1, Q.sub.2, G, R.sup.1, Y, Z, Q.sub.3, n and m are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) inhibitors are also described ##STR00001##
Inventor(s): Pease; Elizabeth Janet (Macclesfield, GB), Breault; Gloria Anne (Macclesfield, GB), Morris; Jeffrey James (Macclesfield, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:10/220,139
Patent Claim Types:
see list of patent claims
Compound; Process; Composition;

Drugs Protected by US Patent 7,153,964

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,153,964

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0004888.4Mar 1, 2000
PCT Information
PCT FiledFebruary 26, 2001PCT Application Number:PCT/GB01/00782
PCT Publication Date:September 07, 2001PCT Publication Number: WO01/64654

International Family Members for US Patent 7,153,964

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 361916 See Plans and Pricing
Australia 3395301 See Plans and Pricing
Australia 765151 See Plans and Pricing
Brazil 0108841 See Plans and Pricing
Brazil PI0108841 See Plans and Pricing
Canada 2399196 See Plans and Pricing
China 100445270 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.